SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, is presenting new data this week showing that its drug candidate HE3286, a novel orally bio-available anti-inflammatory which has previously demonstrated benefit in animal models of rheumatoid arthritis, also provided benefit in an animal model of ulcerative colitis.
